To determine whether the VDR pathway affects in vitro proliferation rates of liver cancer cell lines, HepG2 and Hep3B human liver cancer cell lines were treated with increasing doses of VD and VD-analogs, EB1089 and QW1624F (0.01–1 μM), for 7 days (Fig. 5a). This evidence concerns the gene VDR and liver cancer.